Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

FDA approves a second Alzheimer's drug that can modestly slow disease

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

The Independent UK

Amazon, Meta Spearhead Fresh Batch Of Breakouts As Nvidia Shows Resilience

As Nvidia tests support, Amazon breaks out and Meta moves toward a new buy point, IBD Leaderboard highlights more breakouts.

Investors Business Daily

3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Option Trade Could Make $4,000 With A Pullback

This broken wing butterfly trade has a profit zone between 810 and 890.

Investors Business Daily

Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again

ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.

Investors Business Daily

Weight loss drug could ease sleep apnoea in people with obesity, study says

Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder

The Guardian - UK

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

The World Health Organization and drugmaker Eli Lilly and Co. are warning patients to be wary of fake versions of weight-loss and diabetes medicines

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs

Investors Business Daily

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

Eli Lilly stock seesawed Tuesday after a Food and Drug Administration panel endorsed its Alzheimer's treatment, donanemab.

Investors Business Daily

Alzheimer's drug that can slow disease gets backing from FDA advisers

Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia

The Independent UK

FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug

Eli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer's treatment donanemab outweigh the risks for most patients.

Investors Business Daily

Should a CFO switch industries? For these Fortune 500 finance chiefs, a new sector provided a career boost

Most CFOs have more options than they think, according to an expert.

Fortune

Alphabet’s next CFO Anat Ashkenazi ‘fills a void’ for the company at key time during AI Revolution, says top analyst

Ashkenazi is a 23-year veteran of Eli Lilly and Company.

Fortune

Mutual Funds Keep Buying Up Google, These 2 Other Big Caps

Google stock is a mutual fund favorite and is near a buy point. Two other leading growth stocks top the list of fund favorites.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH

Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.

Fortune

Google and Alphabet’s new CFO is Eli Lilly’s Anat Ashkenazi

Ashkenazi will have the task of investing in the company’s next wave of growth in the AI era.

Investors Business Daily

Costco, Eli Lilly Near New Highs; That Doesn't Scare Mutual Funds

Costco stock is in a buy zone ahead of the earnings report Thursday. Mutual funds like this stock and a few others.

Investors Business Daily

Dow Jones Futures Fall As Target Tumbles; Nvidia Looms Over Stock Market

The Nasdaq hit a new high Tuesday but Target tumbled early Wednesday. Will Nvidia earnings tonight meet lofty hopes?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High

Eli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising test results for a Crohn's treatment.

Barchart

1 'Strong Buy' Dividend Stock to Buy and Hold

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

Investors Business Daily

Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review

The stock market rallied this week, with the Nasdaq regaining its 50-day on a semi-dovish Fed, a tame jobs report and a huge Apple buyback.

StockNews.com

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.

Investors Business Daily

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.

1 … 4 5 6 7

People

Mangeet Kaur BounsMangeet

Margaret Kaczor Andrew

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations